161 related articles for article (PubMed ID: 22095369)
21. Dabigatran effects on the international normalized ratio, activated partial thromboplastin time, thrombin time, and fibrinogen: a multicenter, in vitro study.
Dager WE; Gosselin RC; Kitchen S; Dwyre D
Ann Pharmacother; 2012 Dec; 46(12):1627-36. PubMed ID: 23232017
[TBL] [Abstract][Full Text] [Related]
22. Comparative effects of the human protein C activator, Protac, on the activated partial thromboplastin clotting times of plasmas, with special reference to the dog.
Johnstone IB; Martin CA
Can J Vet Res; 2000 Apr; 64(2):117-22. PubMed ID: 10805251
[TBL] [Abstract][Full Text] [Related]
23. Haemostatic reference intervals in pregnancy.
Szecsi PB; Jørgensen M; Klajnbard A; Andersen MR; Colov NP; Stender S
Thromb Haemost; 2010 Apr; 103(4):718-27. PubMed ID: 20174768
[TBL] [Abstract][Full Text] [Related]
24. Comparison of six dilute russell viper venom time lupus anticoagulant screen/confirm assay kits.
McGlasson DL; Fritsma GA
Semin Thromb Hemost; 2013 Apr; 39(3):315-9. PubMed ID: 23468380
[TBL] [Abstract][Full Text] [Related]
25. Heparin dosing and monitoring for cardiopulmonary bypass. A comparison of techniques with measurement of subclinical plasma coagulation.
Gravlee GP; Haddon WS; Rothberger HK; Mills SA; Rogers AT; Bean VE; Buss DH; Prough DS; Cordell AR
J Thorac Cardiovasc Surg; 1990 Mar; 99(3):518-27. PubMed ID: 2308370
[TBL] [Abstract][Full Text] [Related]
26. Case report: artificial elevation of prothrombin time by telavancin.
Amanatullah DF; Lopez MJ; Gosselin RC; Gupta MC
Clin Orthop Relat Res; 2013 Jan; 471(1):332-5. PubMed ID: 23129464
[TBL] [Abstract][Full Text] [Related]
27. Investigations on blood coagulation in the green iguana (Iguana iguana).
Kubalek S; Mischke R; Fehr M
J Vet Med A Physiol Pathol Clin Med; 2002 May; 49(4):210-6. PubMed ID: 12069264
[TBL] [Abstract][Full Text] [Related]
28. Assessment of laboratory assays to measure rivaroxaban--an oral, direct factor Xa inhibitor.
Samama MM; Martinoli JL; LeFlem L; Guinet C; Plu-Bureau G; Depasse F; Perzborn E
Thromb Haemost; 2010 Apr; 103(4):815-25. PubMed ID: 20135059
[TBL] [Abstract][Full Text] [Related]
29. Methodical aspects of blood coagulation measurements in birds applying commercial reagents--a pilot study.
Guddorf V; Kummerfeld N; Mischke R
Berl Munch Tierarztl Wochenschr; 2014; 127(7-8):322-7. PubMed ID: 25080826
[TBL] [Abstract][Full Text] [Related]
30. Is it acceptable to use coagulation plasma samples stored at room temperature and 4°C for 24 hours for additional prothrombin time, activated partial thromboplastin time, fibrinogen, antithrombin, and D-dimer testing?
Rimac V; Coen Herak D
Int J Lab Hematol; 2017 Oct; 39(5):475-481. PubMed ID: 28488785
[TBL] [Abstract][Full Text] [Related]
31. The monitoring of heparin administration by screening tests in experimental dogs.
Mischke R; Jacobs C
Res Vet Sci; 2001 Apr; 70(2):101-8. PubMed ID: 11356088
[TBL] [Abstract][Full Text] [Related]
32. Do coagulation screening tests detect increased generation of thrombin and plasmin in sick newborn infants?
Schmidt B; Vegh P; Johnston M; Andrew M; Weitz J
Thromb Haemost; 1993 May; 69(5):418-21. PubMed ID: 8322263
[TBL] [Abstract][Full Text] [Related]
33. Sensitivity and specificity of 20-minute whole blood clotting test, prothrombin time, activated partial thromboplastin time tests in diagnosis of defibrination following Malayan pit viper envenoming.
Thongtonyong N; Chinthammitr Y
Toxicon; 2020 Oct; 185():188-192. PubMed ID: 32712023
[TBL] [Abstract][Full Text] [Related]
34. Performance of Platelin LS and dilute Russell's viper venom for the screening of lupus anticoagulant in patients with venous thromboembolism.
Morelli VM; Rodrigues CA; Noguti MA; Matos MF; da Silveira RC; Ribeiro AA; Lourenço DM
Blood Coagul Fibrinolysis; 2007 Jul; 18(5):401-5. PubMed ID: 17581313
[TBL] [Abstract][Full Text] [Related]
35. Influence of temperature and time before centrifugation of specimens for routine coagulation testing.
Salvagno GL; Lippi G; Montagnana M; Franchini M; Poli G; Guidi GC
Int J Lab Hematol; 2009 Aug; 31(4):462-7. PubMed ID: 18371059
[TBL] [Abstract][Full Text] [Related]
36. [Suggestions and propositions to resolve some issues for standardization of prothrombin time and activated partial thromboplastin time].
Kagawa K; Fukutake K
Rinsho Byori; 1999 May; 47(5):431-7. PubMed ID: 10375964
[TBL] [Abstract][Full Text] [Related]
37. Hyperfibrinogenemia and prolonged clotting times in a Turner syndrome patient with hepatocellular carcinoma.
Zhao X; Wang Z; Cao L; Zhang W; Bai X; Dong N; Yu Z; Ruan C
Blood Coagul Fibrinolysis; 2010 Jul; 21(5):398-405. PubMed ID: 20410814
[TBL] [Abstract][Full Text] [Related]
38. Increased thrombin generation and fibrinogen level after therapeutic plasma transfusion: relation to bleeding.
Schols SE; van der Meijden PE; van Oerle R; Curvers J; Heemskerk JW; van Pampus EC
Thromb Haemost; 2008 Jan; 99(1):64-70. PubMed ID: 18217136
[TBL] [Abstract][Full Text] [Related]
39. Comparison between a one-point dilute phospholipid APTT and the dilute Russell viper venom time for verification of lupus anticoagulants.
Alving BM; Barr CF; Johansen LE; Tang DB
Thromb Haemost; 1992 Jun; 67(6):672-8. PubMed ID: 1509408
[TBL] [Abstract][Full Text] [Related]
40. Effects of reagent and instrument on prothrombin times, activated partial thromboplastin times and patient/control ratios.
Naghibi F; Han Y; Dodds WJ; Lawrence CE
Thromb Haemost; 1988 Jun; 59(3):455-63. PubMed ID: 3187932
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
